BeiGene, Ltd. (BGNE) Analysts See $-1.74 EPS

March 13, 2018 - By Darrin Black

 BeiGene, Ltd. (BGNE) Analysts See $ 1.74 EPS

Analysts expect BeiGene, Ltd. (NASDAQ:BGNE) to report $-1.74 EPS on March, 28.They anticipate $0.69 EPS change or 65.71 % from last quarter’s $-1.05 EPS. After having $2.54 EPS previously, BeiGene, Ltd.’s analysts see -168.50 % EPS growth. The stock increased 0.76% or $1.18 during the last trading session, reaching $155.48. About 311,745 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 36.36% since March 13, 2017 and is uptrending. It has outperformed by 19.66% the S&P500.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $8.27 billion. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

More notable recent BeiGene, Ltd. (NASDAQ:BGNE) news were published by: which released: “BeiGene Ltd. ADR” on February 03, 2016, also with their article: “BeiGene Ltd. ADR BGNE (US: Nasdaq)” published on January 31, 2016, published: “Beigene Ltd (ADR) (NASDAQ:BGNE): We Made Alerts For Medium term And Made 90 …” on February 24, 2018. More interesting news about BeiGene, Ltd. (NASDAQ:BGNE) were released by: and their article: “Citi Appointed Depositary Bank for BeiGene, Ltd.’s Sponsored ADR Program” published on February 08, 2016 as well as‘s news article titled: “BeiGene, first IPO of 2016, begins trading above issue price” with publication date: February 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: